Navigation Links
Hologic Announces Fourth Quarter and Fiscal 2010 Operating Results
Date:11/8/2010

ainties regarding the recently enacted healthcare reform legislation and associated tax provisions; changes in guidelines, recommendations and studies published by various organizations that could affect the use of the Company's products; the Company's ability to integrate its acquisitions and business combinations effectively; uncertainties inherent in the development of new products and the enhancement of existing products, including FDA approval and/or clearance and other regulatory risks, technical risks, cost overruns and delays; the risk that newly introduced products may contain undetected errors or defects or otherwise not perform as anticipated; manufacturing risks, including the Company's reliance on a single or limited source of supply for key components, and the need to comply with especially high standards for the manufacture of many of its products; the Company's ability to predict accurately the demand for its products, and products under development, and to develop strategies to address its markets successfully; the early stage of market development for certain of the Company's products; the risk of adverse events and product liability claims; risks related to the use and protection of intellectual property; expenses and uncertainties relating to litigation; technical innovations that could render products marketed or under development by the Company obsolete; competition; the risks of conducting business internationally, including the effect of exchange rate fluctuations on those operations; financing risks, including the Company's obligation to meet financial covenants under the Company's financing arrangements and leases; and the Company's ability to attract and retain qualified personnel.

The risks and uncertainties included above are not exhaustive. Other factors that could adversely affect the Company's business and prospects are described in the Company's filings with the Securities and Exchange Commission. The Company expressly disclai
'/>"/>

SOURCE Hologic, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related medicine technology :

1. Hologic Announces Long-term, Five-year Results from MammoSite® ASBS Registry Study
2. Hologic to Host Investor Presentation at RSNA 2010
3. Hologic to Release Fourth Quarter Fiscal 2010 Operating Results on Monday, November 8, 2010
4. Hologics Selenia Dimensions (3-D) Digital Mammography Tomosynthesis System Receives Favorable Votes From FDA Advisory Panel
5. Hologic to Present at the 2010 Morgan Stanley Global Healthcare Conference
6. Ethicon Endo-Surgery Announces Agreement with Hologic Inc. To Resolve Patent Disputes
7. Hologic Announces Decision in Patent Infringement Suit
8. Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimers Disease
9. New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity
10. Hologic to Feature Adiana(R) Permanent Contraception System at AAGL 2009
11. Hologic to Present at NASDAQ OMX 23rd Investor Program in London
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 19, 2014  Advanced Medical Isotope Corporation ("AMIC") ... primarily in the development of brachytherapy devices and ... announced that a Life Sciences Discovery Fund (LSDF) ... which AMIC is the commercialization partner.  The award ... the proposal titled "Optimized Injectable Radiogels for High-dose ...
(Date:12/19/2014)... WESTMINSTER, Colo. , Dec. 19, 2014  Monarch ... (f/k/a Cannabis Kinetics Corp.) is pleased to provide this ... for continued growth in 2015. "Over this ... corporate goals and I am extremely proud to say ... diversified position today than it has ever been," stated ...
(Date:12/19/2014)... , Dec. 18, 2014  Sage Analytics ... generation of equipment for the testing of marijuana ... of the new Luminary™ Profiler, the industry,s first ... measurement in a cost-effective, portable unit. ... specific needs of the cannabis industry, the Luminary™ ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 2Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 3Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2
... symptom control ... with combination therapy ... published study presents,data demonstrating that patients with Chronic Obstructive ... bronchodilation and symptom control when treated with a,combination of ...
... a Benefit,of Anti-Tumor Necrosis Factor Therapies on Absenteeism Among Employees with ... ... a new analysis of the,Active Ulcerative Colitis Trials (ACT 1 and ... patients with moderately to severely active,ulcerative colitis (UC) receiving REMICADE(R) (infliximab) ...
Cached Medicine Technology:Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 2Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 3Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 4Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 5Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 6Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 7New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 2New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 3New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 4New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 5New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 6New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 7New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 8
(Date:12/21/2014)... (PRWEB) December 21, 2014 Hundreds ... product liability claims involving a class of Type ... to move forward in a federal multidistrict litigation ... of California, Bernstein Liebhard LLP reports. According to ... established a data cut-off date of February 27, ...
(Date:12/21/2014)... AlignLife of Norton Shores is spreading Christmas ... time helping people get their health back. Mission for ... serving those persons in Muskegon County who are unable to ... of life. Dr. Michael Rykse wanted to do a Toy ... and he knew he found that when he heard what ...
(Date:12/21/2014)... 2014 SCI explores disability ... and systemic barriers for disabled athletes with Aaron ... has a condition called juvenile macular degeneration, where he ... he adapted his athletic ambitions to his vision and ... triathlon to pioneer the way for other blind and ...
(Date:12/21/2014)... The Oncology Institute of Hope and Innovation ... and Whittier offices. The Hope for the Holidays Toy Drive ... and their families during the holiday season. This year, the ... children between both offices. This event continues to be successful ... service team, store managers and assistant managers came out and ...
(Date:12/20/2014)... MissyDress, a distinguished special dress supplier, has just ... has drastically cut prices to all its prom dresses ... 30, 2015. Many of the hottest styles are sold ... dresses, and more. , A spokesman for MissyDress says, ... A-line princess prom dresses or sweetheart chiffon prom dresses, ...
Breaking Medicine News(10 mins):Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 2Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 3Health News:Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Report 4Health News:AlignLife of Norton Shores Makes a Brighter Christmas for Kids in Muskegon 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 3Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2
... SAN DIEGO, Feb. 26 AMN Healthcare Services,Inc. (NYSE: ... today,reported revenue for the fourth quarter of 2007 of ... $283.5 million reported for the,same quarter last year, and ... in the third quarter. The sequential decline in revenue,was ...
... YORK, Feb. 26 The following is a statement being,issued ... disease, I remain deeply committed to alleviating suffering from ... my heart, that I have been,sincere and honest in my ... ad campaign Pfizer tastefully presented to the public, using,beautiful natural ...
... MEDX ) announced today its financial results for the ... of $152.1 million, or $1.20 per share, from Medarex,s,sale of ... Medarex,s net loss for the year ended December 31, 2007 ... net loss of $181.7 million,or ($1.50) per share for 2006. ...
... DATA ), a technology and services company focused ... reported its,operating results for the fourth quarter and full ... December 31, 2007, revenue decreased,approximately 54% to $1,839,000 and ... per share on both a basic and diluted basis. ...
... finds that if first antidepressant doesn,t work, try a ... News) -- If a depressed teen doesn,t respond to ... new research suggests there,s still hope. , Switching medications ... the most effective alternative, although just switching medications also ...
... Ironman Remains Honorary Spokesperson for Lung Cancer,Alliance, ... proudly announced the continuation of its Face in ... Cal Ripken, Jr. Ripken,continues to headline a nationwide ... cancer., Ripken, known as the Ironman because ...
Cached Medicine News:Health News:AMN Healthcare Reports Fourth Quarter and Year End 2007 Results; Provides Full Year 2008 Guidance 2Health News:AMN Healthcare Reports Fourth Quarter and Year End 2007 Results; Provides Full Year 2008 Guidance 3Health News:AMN Healthcare Reports Fourth Quarter and Year End 2007 Results; Provides Full Year 2008 Guidance 4Health News:AMN Healthcare Reports Fourth Quarter and Year End 2007 Results; Provides Full Year 2008 Guidance 5Health News:AMN Healthcare Reports Fourth Quarter and Year End 2007 Results; Provides Full Year 2008 Guidance 6Health News:AMN Healthcare Reports Fourth Quarter and Year End 2007 Results; Provides Full Year 2008 Guidance 7Health News:AMN Healthcare Reports Fourth Quarter and Year End 2007 Results; Provides Full Year 2008 Guidance 8Health News:AMN Healthcare Reports Fourth Quarter and Year End 2007 Results; Provides Full Year 2008 Guidance 9Health News:AMN Healthcare Reports Fourth Quarter and Year End 2007 Results; Provides Full Year 2008 Guidance 10Health News:AMN Healthcare Reports Fourth Quarter and Year End 2007 Results; Provides Full Year 2008 Guidance 11Health News:AMN Healthcare Reports Fourth Quarter and Year End 2007 Results; Provides Full Year 2008 Guidance 12Health News:AMN Healthcare Reports Fourth Quarter and Year End 2007 Results; Provides Full Year 2008 Guidance 13Health News:AMN Healthcare Reports Fourth Quarter and Year End 2007 Results; Provides Full Year 2008 Guidance 14Health News:AMN Healthcare Reports Fourth Quarter and Year End 2007 Results; Provides Full Year 2008 Guidance 15Health News:Statement of Robert Jarvik, MD, President and CEO of Jarvik Heart, Inc. Regarding the Lipitor DTC Advertisements 2Health News:Statement of Robert Jarvik, MD, President and CEO of Jarvik Heart, Inc. Regarding the Lipitor DTC Advertisements 3Health News:Medarex Announces 2007 Fourth Quarter and Year End Financial Results 2Health News:Medarex Announces 2007 Fourth Quarter and Year End Financial Results 3Health News:Medarex Announces 2007 Fourth Quarter and Year End Financial Results 4Health News:Medarex Announces 2007 Fourth Quarter and Year End Financial Results 5Health News:Medarex Announces 2007 Fourth Quarter and Year End Financial Results 6Health News:Medarex Announces 2007 Fourth Quarter and Year End Financial Results 7Health News:Medarex Announces 2007 Fourth Quarter and Year End Financial Results 8Health News:Medarex Announces 2007 Fourth Quarter and Year End Financial Results 9Health News:Medarex Announces 2007 Fourth Quarter and Year End Financial Results 10Health News:Medarex Announces 2007 Fourth Quarter and Year End Financial Results 11Health News:Medarex Announces 2007 Fourth Quarter and Year End Financial Results 12Health News:DATATRAK International Reports Fourth Quarter and Full Year Results for 2007 2Health News:DATATRAK International Reports Fourth Quarter and Full Year Results for 2007 3Health News:DATATRAK International Reports Fourth Quarter and Full Year Results for 2007 4Health News:DATATRAK International Reports Fourth Quarter and Full Year Results for 2007 5Health News:DATATRAK International Reports Fourth Quarter and Full Year Results for 2007 6Health News:DATATRAK International Reports Fourth Quarter and Full Year Results for 2007 7Health News:DATATRAK International Reports Fourth Quarter and Full Year Results for 2007 8Health News:New Hope for Depressed Teens 2
... tip is specially rounded, extra ... wound and manipulation in the ... flexible tubing 25cm, ID - ... annular rings start .85mm ...
For administering anesthetic agents into the posterior sub-Tenon's space 20G x 1in (.90 x 25mm)...
... This all digital single plane C-arm angiography ... cardiac imaging performance and an expansive range ... cardiac angiography to ECG triggered. ... Detector technology,State of the art dynamic Flat ...
For diagnostic and operative treatment of hand and wrist bones. The use of this distraction device allows fracture reduction or widening of the space between bones....
Medicine Products: